体外膜氧合治疗COVID-19:与体外生命支持组织登记库中非COVID-19相关病毒性急性呼吸窘迫综合征的结局比较
基于体外生命支持组织(ELSO)登记库的回顾性观察性队列研究,纳入2017年1月至2021年12月因病毒介导的ARDS需要ECMO的成人患者9291例,其中非COVID-19病毒性ARDS 1155例、COVID-19相关ARDS 8136例。COVID-19组ECMO支持时间更长(19.6天 vs 10.7天)、ECMO支持期间死亡率更高(44.4% vs 27.5%)、住院死亡率更高(50.2% vs 34.5%),且机械和临床并发症(膜肺故障、气胸、颅内出血、重叠感染)更多。校正ECMO前疾病严重度后,COVID-19患者住院死亡风险为非COVID-19病毒性ARDS的两倍以上。作者认为需进一步研究以识别最可能从ECMO获益的COVID-19患者表型。
要点
- COVID-19组ECMO支持时间19.6天(IQR 10.1-34.0天)长于非COVID-19病毒性ARDS组10.7天(IQR 6.3-19.7天),p<0.001。
- COVID-19组ECMO支持期间死亡率44.4%,高于非COVID-19病毒性ARDS组27.5%,p<0.001。
- COVID-19组住院死亡率50.2%,高于非COVID-19病毒性ARDS组34.5%,p<0.001。
- COVID-19患者更易发生机械和临床并发症,包括膜肺故障、气胸、颅内出血和重叠感染。
- 校正ECMO前疾病严重度后,COVID-19患者住院死亡风险为非COVID-19病毒性ARDS的两倍以上。
适用人群与场景
- 体外生命支持组织(ELSO)登记库中2017年1月至2021年12月因病毒介导的ARDS需要ECMO的成人患者9291例,其中非COVID-19病毒性ARDS 1155例、COVID-19相关ARDS 8136例。
研究设计与关键结果
- 研究设计为回顾性观察性队列研究,数据来自体外生命支持组织登记库,纳入9291例因病毒介导的ARDS需要ECMO的成人患者。
- 主要结局为ECMO支持期间死亡和出院前死亡,采用时间-事件分析和逻辑回归比较两组结局。
- COVID-19组ECMO支持时间19.6天(IQR 10.1-34.0天)长于非COVID-19病毒性ARDS组10.7天(IQR 6.3-19.7天),p<0.001。
- COVID-19组ECMO支持期间死亡率44.4%,高于非COVID-19病毒性ARDS组27.5%,p<0.001。
- COVID-19组住院死亡率50.2%,高于非COVID-19病毒性ARDS组34.5%,p<0.001。
- COVID-19患者更易发生机械和临床并发症,包括膜肺故障、气胸、颅内出血和重叠感染。
- 校正ECMO前疾病严重度后,COVID-19患者住院死亡风险为非COVID-19病毒性ARDS的两倍以上。
证据类型、等级与局限
- 证据类型:回顾性观察性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,需进一步研究COVID-19患者以识别最可能从ECMO获益的患者表型,并更好地界定ECMO在该疾病过程中的作用。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: To compare complications and mortality between patients that required extracorporeal membrane oxygenation (ECMO) support for acute respiratory distress syndrome (ARDS) due to COVID-19 and non-COVID-19 viral pathogens.
DESIGN: Retrospective observational cohort study.
SETTING: Adult patients in the Extracorporeal Life Support Organization registry.
PATIENTS: Nine-thousand two-hundred ninety-one patients that required ECMO for viral mediated ARDS between January 2017 and December 2021.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: The primary outcomes of interest were mortality during ECMO support and prior to hospital discharge. Time-to-event analysis and logistic regression were used to compare outcomes between the groups. Among 9,291 included patients, 1,155 required ECMO for non-COVID-19 viral ARDS and 8,136 required ECMO for ARDS due to COVID-19. Patients with COVID-19 had longer duration of ECMO (19.6 d [interquartile range (IQR), 10.1-34.0 d] vs 10.7 d [IQR, 6.3-19.7 d]; p < 0.001), higher mortality during ECMO support (44.4% vs 27.5%; p < 0.001), and higher in-hospital mortality (50.2% vs 34.5%; p < 0.001). Further, patients with COVID-19 were more likely to experience mechanical and clinical complications (membrane lung failure, pneumothorax, intracranial hemorrhage, and superimposed infection). After adjusting for pre-ECMO disease severity, patients with COVID-19 were more than two times as likely to die in the hospital compared with patients with non-COVID-19 viral ARDS.
CONCLUSIONS: Patients with COVID-19 that require ECMO have longer duration of ECMO, more complications, and higher in-hospital mortality compared with patients with non-COVID-19-related viral ARDS. Further study in patients with COVID-19 is critical to identify the patient phenotype most likely to benefit from ECMO and to better define the role of ECMO in the management of this disease process.
参考来源
- Chandel A, Puri N, Damuth E, et al. Extracorporeal Membrane Oxygenation for COVID-19: Comparison of Outcomes to Non-COVID-19-Related Viral Acute Respiratory Distress Syndrome From the Extracorporeal Life Support Organization Registry. Crit Care Explor. 2023. PMID: 36760815. doi:10.1097/CCE.0000000000000861
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。